CART-TnMUC1

N/A

Report date: 2023/04/20 20:00:26

Base Information

Drug NameCART-TnMUC1

Drug Alias NameTnMUC1 CAR-TAnti-TnMUC1 chimeric antigen receptor T-cell therapy - Tmunity TherapeuticsTnMUC-1 targetted CAR T-cell therapy - Tmunity TherapeuticsAnti-TnMUC-1 CAR T cell therapy - Tmunity Therapeutics

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-MUC1

TargetsMucin-1

Therapy Area/IndicationsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Minnesota University Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKite Pharma

Active IndicationsN/A

Inactive IndicationsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6]

Other Information

ATC CodeN/A